预约演示
NICE recommends Ebglyss for atopic dermatitis patients
上市批准并购
Around 5.2 million adults in the UK have moderate to severe atopic dermatitis. Image credit: Shutterstock / Kmpzzz.
England’s National Institute for Health and Care Excellence atopic dermatitisended Almirall’s Ebglyss (lebrikizumab) for patients with moderate to severe atopic dermatitis, giving NHS patients another biological therapy option.
In line with NICE guidelines, the NHS will now have 90 days to make the treatment available toEbglysstslebrikizumabatopic dermatitis
Patients over 12 years of age who have not responded to or are not able to take systemic immunosuppressants will be eligible for the therapy, as per a 10 July press release.
Monoclonal antibody Ebgylss will join Sanofi / Regeneron’s Dupixent (dupilumab) and Leo Pharma’s Adbry (tralokinumab) as interleukin-targeting options for treating the skin condition. The Janus kinase (JAK) inhibitors Cibinqo (abrocitinib), Olumiant (baricitinib), and Rinvoq (upadacitinib) developed by Pfizer, Eli Lilly, and AbbVie, respectively, are also recommended by NICE.
Atopic dermatitis, also known as atopiSanofima,RegeneronflaDupixentskdupilumabion chLeo Pharmad by intense itching. It has an estimated prevalence of up to 4.4% among adults in the EU. In Janus kinase (JAK)nd 5.2 milliCibinqotsabrocitinibateOlumiantrebaricitinibmatitisRinvoqupadacitinibPfizerEliLillyAbbVie
Atopic dermatitis “addresses curratopic eczemaOPD biolinflammatory skin conditionitchingatopic dermatitis
Ebglyss, which was approved in Europe in October 2023, and then two months later in the UK, works by inhibiting interleukin-13 (IL-13) signalling. IL-13 pathways play an important role in inflammation, driving the type-2 inflammatory loop in the skin. Adbry similarly targets IL-13 while Dupixent inhibits IL-13 and IL-4.
Peltopepimut-sczemISA PharmaceuticalsxecutCervical Cancertor said: “It’s important we have a range of treatment options, so patients have the chance to access a treatment that works well for them.”
Almirall licensed the rights to develop and commercialise Ebglyss in dermatology indications, including atopic dermatitis, in Europe from Dermira in 2019. Dermira was then acquired by Eli Lilly, the latter retaining drug rights in the US and the rest of the world.
Ebglyss is forecast to reach blockbuster status by 2026, according to GlobalData’s Pharma Intelligence Centre. Binterleukin-13 (IL-13)edicted to geIL-13e nearly $3.4bn in global sales.inflammationAdbryIL-13DupixentIL-13IL-4
GlobNational Eczema SocietyEczemaarent company of Pharmaceutical Technology.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。